Sigma Planning Corp Sells 46,315 Shares of Liquidia Co. (NASDAQ:LQDA)

Sigma Planning Corp lowered its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 42.3% during the third quarter, HoldingsChannel reports. The fund owned 63,095 shares of the company’s stock after selling 46,315 shares during the quarter. Sigma Planning Corp’s holdings in Liquidia were worth $631,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Whitcomb & Hess Inc. boosted its stake in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares in the last quarter. American International Group Inc. boosted its stake in Liquidia by 5.2% during the first quarter. American International Group Inc. now owns 24,806 shares of the company’s stock worth $366,000 after buying an additional 1,215 shares in the last quarter. Arizona State Retirement System boosted its stake in Liquidia by 10.7% during the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after buying an additional 1,341 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in Liquidia by 6.6% during the first quarter. Bleakley Financial Group LLC now owns 33,250 shares of the company’s stock worth $490,000 after buying an additional 2,057 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in Liquidia during the second quarter worth $27,000. Institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on LQDA. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Liquidia in a research note on Thursday. Scotiabank began coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Lifesci Capital began coverage on shares of Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, BTIG Research reduced their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Insider Buying and Selling

In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the sale, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. The trade was a 1.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were purchased at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. The trade was a 2.19 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 21,551 shares of company stock worth $236,021 in the last 90 days. Corporate insiders own 30.10% of the company’s stock.

Liquidia Stock Down 2.4 %

Shares of NASDAQ LQDA opened at $10.03 on Friday. The firm’s 50-day simple moving average is $10.48 and its 200 day simple moving average is $11.52. The company has a market cap of $769.86 million, a price-to-earnings ratio of -6.38 and a beta of 0.21. Liquidia Co. has a 12-month low of $6.10 and a 12-month high of $16.99.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).